13F-HR filed by Bain Capital Life Sciences Investors, LLC
Bain Capital Life Sciences Investors, LLC filed this 13F-HR for the quarter ended 2021-06-30, filed 2021-08-16, with 30 holding rows worth $1,526,199,000.
- Accession
- 0000950123-21-011522
- Filer
- CIK 1703031
- Filed
- 2021-08-16
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2021
A holdings report, 30 entries on the cover page, a total value of $1,526,199,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,526,199,000 with VALUE read as thousands by filing date, 13F file number 028-18477. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerBain Capital Life Sciences Partners, LP 028-18476
- included managerBain Capital Life Sciences Fund, L.P. 028-18478
- included managerBC SW, LP 028-20270
- included managerBain Capital Life Sciences Investors II, LLC 028-20816
- included managerBain Capital Life Sciences Fund II, L.P. 028-20814
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS INC | 85205L107 | COM | 5,831,307 | $480,558,000 | thousands by filing date | |
| ATEA PHARMACEUTICALS INC | 04683R106 | COMMON STOCK | 5,615,659 | $120,624,000 | thousands by filing date | |
| DYNAVAX TECHNOLOGIES CORP | 268158201 | COM NEW | 11,771,708 | $115,951,000 | thousands by filing date | |
| DICERNA PHARMACEUTICALS INC | 253031108 | COM | 3,080,237 | $114,954,000 | thousands by filing date | |
| ARCUTIS BIOTHERAPEUTICS INC | 03969K108 | COM | 3,979,292 | $108,595,000 | thousands by filing date | |
| ANNEXON INC | 03589W102 | COM | 3,241,628 | $72,969,000 | thousands by filing date | |
| C4 THERAPEUTICS INC | 12529R107 | COM STK | 1,642,209 | $62,141,000 | thousands by filing date | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 3,180,601 | $59,255,000 | thousands by filing date | |
| Mersana Therapeutics Inc | 59045L106 | Common Stock | 3,695,667 | $50,187,000 | thousands by filing date | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 1,284,314 | $34,073,000 | thousands by filing date | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 1,679,701 | $31,662,000 | thousands by filing date | |
| SYROS PHARMACEUTICALS INC | 87184Q107 | COM | 5,785,036 | $31,528,000 | thousands by filing date | |
| SOLID BIOSCIENCES INC COM NEW | 83422E105 | Stock | 7,929,918 | $29,024,000 | thousands by filing date | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 1,431,058 | $25,673,000 | thousands by filing date | |
| APTINYX INC | 03836N103 | COM | 8,891,758 | $25,164,000 | thousands by filing date | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 479,605 | $23,261,000 | thousands by filing date | |
| NAUTILUS BIOTECHNOLOGY INC | 63909J108 | COM | 2,000,000 | $20,200,000 | thousands by filing date | |
| SAVARA INC | 805111101 | COM | 11,622,598 | $19,758,000 | thousands by filing date | |
| AEGLEA BIOTHERAPEUTICS INC | 00773J103 | COM | 2,700,000 | $18,792,000 | thousands by filing date | |
| BLUEBIRD BIO INC | 09609G100 | COM | 538,179 | $17,211,000 | thousands by filing date | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 2,119,540 | $13,777,000 | thousands by filing date | |
| BCTG ACQUISITION CORP | 05492W103 | COM | 921,790 | $10,490,000 | thousands by filing date | |
| RESEARCH ALLIANCE CORP II | 760873109 | CMN | 1,000,000 | $10,140,000 | thousands by filing date | |
| ARYA SCIENCES ACQU CORP IV | G31659108 | COM | 700,000 | $7,504,000 | thousands by filing date | |
| BCLS ACQUISITION CORP | G0904B105 | CMN | 487,500 | $5,133,000 | thousands by filing date | |
| PANACEA ACQUISITION CORP II | G6882C106 | COM | 500,000 | $5,010,000 | thousands by filing date | |
| OMEGA ALPHA SPAC | G6749V107 | CL A | 400,000 | $3,980,000 | thousands by filing date | |
| FRAZIER LIFESCIENCES ACQU CORP UNIT EXP 120925 | G3710A121 | Stock | 300,000 | $3,015,000 | thousands by filing date | |
| JIYA ACQUISITION CORP | 47760M102 | CMN | 300,000 | $2,982,000 | thousands by filing date | |
| MOONLAKE IMMUNOTHERAPEUTICS | G4444C102 | COM | 250,000 | $2,588,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-21-011522 | this filing | 2021-08-16 | acceptance time not in the bulk data set |